Keyword Analysis & Research: luspatercept

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
luspatercept	1.41	0.1	8678	73	12

Keyword	CPC	PCC	Volume	Score
luspatercept	1.25	0.8	4454	71
luspatercept-aamt	0.58	0.6	3618	68
luspatercept package insert	0.48	0.8	730	45
luspatercept mds	1.76	0.3	696	86
luspatercept mechanism of action	1.52	0.1	9218	25
luspatercept moa	0.74	0.3	1535	94
luspatercept cost	0.82	0.1	3784	56
luspatercept reblozyl	0.92	0.9	6952	88
luspatercept side effects	0.74	0.3	3996	40
luspatercept fda approval	1.71	0.6	3466	62
luspatercept injection	1.69	1	4629	43
luspatercept dosing	1.34	0.5	4079	47
luspatercept ema	0.12	0.7	3354	60
luspatercept pi	0.49	1	2602	84
luspatercept approval	0.09	0.1	9648	40
luspatercept myelofibrosis	0.04	0.1	326	12
luspatercept j code	0.49	0.7	4405	4
luspatercept fachinformation	1.6	1	3619	86
luspatercept label	0.44	0.7	7437	44
luspatercept fda label	0.83	0.8	6774	24

Luspatercept - Wikipedia
wikipedia.org

https://en.m.wikipedia.org/wiki/Luspatercept

WebLuspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

DA: 47 PA: 30 MOZ Rank: 66

Luspatercept Uses, Side Effects & Warnings - Drugs.com
drugs.com

https://www.drugs.com/mtm/luspatercept.html

WebDec 6, 2023 · Luspatercept is used to treat anemia (lack of red blood cells) in adults with beta thalassemia who need to have regular red blood cell transfusions. Luspatercept may also be used for purposes not listed in this medication guide. Luspatercept side effects.

DA: 74 PA: 29 MOZ Rank: 10

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1908892

WebJan 8, 2020 · Luspatercept is a recombinant fusion protein that binds select transforming growth factor β superfamily ligands to decrease SMAD2 and SMAD3 signaling, thereby enabling erythroid maturation by...

DA: 66 PA: 46 MOZ Rank: 36

Luspatercept - StatPearls - NCBI Bookshelf
nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK560635/

WebJul 10, 2023 · Luspatercept is a medication used to manage and treat anemia in myelodysplastic syndromes, primary myelofibrosis, and beta-thalassemia. It is a recombinant fusion protein that binds transforming growth factor-beta ligands to reduce SMAD2 and SMAD3 signaling.

DA: 97 PA: 71 MOZ Rank: 39

Luspatercept: Uses, Interactions, Mechanism of Action
drugbank.com

https://go.drugbank.com/drugs/DB12281

WebOct 20, 2016 · Luspatercept is an erythroid maturation agent used to treat anemia secondary to beta thalassemia, myelodysplastic syndromes, and neoplasms. Brand Names. Reblozyl. Generic Name. Luspatercept. DrugBank Accession Number. …

DA: 36 PA: 13 MOZ Rank: 95

FDA approves luspatercept-aamt for anemia in adults with MDS
fda.gov

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-luspatercept-aamt-anemia-adults-mds

WebOn April 3, 2020, the Food and Drug Administration approved luspatercept-aamt (REBLOZYL, Celgene Corporation) for the treatment of anemia failing an erythropoiesis stimulating agent and...

DA: 1 PA: 42 MOZ Rank: 54

The use of luspatercept for thalassemia in adults
ashpublications.org

https://ashpublications.org/bloodadvances/article/5/1/326/474891/The-use-of-luspatercept-for-thalassemia-in-adults

WebJan 12, 2021 · Luspatercept is an activin receptor ligand trap that has been shown to enhance late-stage erythropoiesis in animal models of β-thalassemia. A multicenter, international, phase 2 dose-finding study was initiated in adult patients with β-thalassemia, either non–transfusion-dependent thalassemia (NTDT) or transfusion-dependent thalassemia (TDT).

DA: 45 PA: 88 MOZ Rank: 63

A Phase 3 Trial of Luspatercept in Patients with Transfusion …
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1910182

WebMar 25, 2020 · Luspatercept is a recombinant fusion protein that binds to select transforming growth factor β superfamily ligands and enhances late-stage erythropoiesis.

DA: 92 PA: 94 MOZ Rank: 77

Luspatercept-aamt - NCI - National Cancer Institute
cancer.gov

https://www.cancer.gov/about-cancer/treatment/drugs/luspatercept-aamt

WebLuspatercept-aamt is approved to treat: Anemia caused by certain types of myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. It is used in adults who need regular red blood cell transfusions and whose anemia did not respond to or cannot be treated with an erythropoiesis-stimulating agent.

DA: 19 PA: 67 MOZ Rank: 47

Reblozyl (luspatercept) dosing, indications, interactions, adverse
medscape.com

https://reference.medscape.com/drug/reblozyl-luspatercept-1000359

WebReblozyl (luspatercept) dosing, indications, interactions, adverse effects, and more. Limitation of use. Not for use as substitute for RBC transfusions in patients requiring immediate...

DA: 10 PA: 33 MOZ Rank: 88